Cancer stem cell markers in prostate cancer: An immunohistochemical study of ALDH1, SOX2 and EZH2

Pathology

Volumn 47, Issue 7, 2015, Pages 622-628

  Matsika, Admire ^a,b,c   Srinivasan, Bhuvana ^a   Day, Christopher ^a,b,c   Mader, Sabrina Ann ^d   Kiernan, Deirdre Margaret ^d   Broomfield, Amy ^a   Fu, Jinlin ^c   Hooper, John D ^c   Kench, James G ^e   Samaratunga, Hemamali ^c,f  

^a MATER HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d MATER ADULT HOSPITAL   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f Aquesta Pathology   (Australia)

Author keywords

Adenocarcinoma; ALDH1; androgen receptor; cancer stem cell theory; cancer stem cells; EZH2; immunohistochemistry; prognostic markers; prostate cancer; SOX2

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; EZH2 PROTEIN, HUMAN; ISOENZYME; POLYCOMB REPRESSIVE COMPLEX 2; RETINAL DEHYDROGENASE; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; BIOSYNTHESIS; CANCER STEM CELL; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; ADULT; AGED; BIOMARKERS, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; POLYCOMB REPRESSIVE COMPLEX 2; PROSTATIC NEOPLASMS; RETINAL DEHYDROGENASE; SOXB1 TRANSCRIPTION FACTORS;

EID: 84957647695     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000325     Document Type: Article

References (48)

1. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347: 1593-603.
2. Tu SM, Lin SH. Prostate cancer stem cells. Clin Genitourin Cancer 2012; 10: 69-76.
3. De Marzo AM, Nelson WG, Meeker AK, Coffey DS. Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998; 160: 2381-92.
4. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol 2011; 223: 147-61.
5. La Porta CA. Thoughts about cancer stem cells in solid tumors. World J Stem Cells 2012; 4: 17-20.
6. Sharpe B, Beresford M, Bowen R, Mitchard J, Chalmers AD. Searching for prostate cancer stem cells: markers and methods. Stem Cell Rev 2013; 9: 721-30.
7. Yoshida A, Hsu LC, Dave V. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme 1992; 46: 239-44.
8. Moreb JS, Mohuczy D, Ostmark B, Zucali JR. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol 2007; 59: 127-36.
9. Armstrong L, Stojkovic M, Dimmick I, et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004; 22: 1142-51.
10. Cheung AM, Wan TS, Leung JC, et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007; 21: 1423-30.
11. De Brot M, Rocha RM, Soares FA, Gobbi H. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers. Pathology 2012; 44: 303-12.
12. Yoshida A, Hsu LC, Yanagawa Y. Biological role of human cytosolic aldehyde dehydrogenase 1: hormonal response, retinal oxidation and implication in testicular feminization. Adv Exp Med Biol 1993; 328: 37-44.
13. Li T, Su Y, Mei Y, et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 2010; 90: 234-44.
14. Nishida S, Hirohashi Y, Torigoe T, et al. Gene expression profiles of prostate cancer stem cells isolated by aldehyde dehydrogenase activity assay. J Urol 2012; 188: 294-9.
15. van den Hoogen C, van der Horst G, Cheung H, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010; 70: 5163-73.
16. Chen H, Rossier C, Antonarakis SE. Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22. 2. Genomics 1996; 38: 30-7.
17. Chou RH, Yu YL, Hung MC. The roles of EZH2 in cell lineage commitment. Am J Transl Res 2011; 3: 243-50.
18. Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell 2013; 4: 331-41.
19. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007; 67: 547-56.
20. Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006; 24: 268-73.
21. Stevanovic M, Zuffardi O, Collignon J, Lovell-Badge R, Goodfellow P. The cDNA sequence and chromosomal location of the human SOX2 gene. Mamm Genome 1994; 5: 640-2.
22. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122: 947-56.
23. Rybak AP, Tang D. SOX2 plays a critical role in EGFR-mediated self-renewal of human prostate cancer stem-like cells. Cell Signal 2013; 25: 2734-42.
24. Jia X, Li X, Xu Y, et al. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 2011; 3: 230-8.
25. Australian Institute of Health and Welfare (AIHW). Cancer in Australia: an overview 2012. Cat no. CAN 70. Canberra: AIHW, 2012.
26. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
27. Ahmed HU. Prostate cancer: Time for active surveillance of intermediate-risk disease? Nat Rev Urol 2013; 10: 6-8.
28. Dall'Era MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012; 62: 976-83.
29. Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, Epstein JI. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol 2009; 182: 1364-70.
30. Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol 1993; 150: 135-41.
31. Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010; 649.
32. Wheeler TM, Dillioglugil O, Kattan MW, et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol 1998; 29: 856-62.
33. Bremer B, Tacha D. ALDH1A1 as a marker of stem cells in prostate cancer: correlation with Gleason scores and tumor stage and relevance for patient outcome. Arch Pathol Lab Med 2011; 135: 1102-230; (Abstr 761).
34. Le Magnen C, Bubendorf L, Rentsch CA, et al. Characterization and clinical relevance of ALDHbright populations in prostate cancer. Clin Cancer Res 2013; 19: 5361-71.
35. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001; 166: 2472-83.
36. Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 2005; 173: 10-20.
37. Dakhova O, Rowley D, Ittmann M. Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo. Clin Cancer Res 2013; 22: 22.
38. Wolters T, Vissers KJ, Bangma CH, Schroder FH, van Leenders GJ. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. BJU Int 2010; 106: 280-6.
39. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008; 122: 595-602.
40. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-9.
41. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003; 95: 661-8.
42. Karanikolas BD, Figueiredo ML, Wu L. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate 2010; 70: 675-88.
43. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 2006; 45: 639-45.
44. Tamgue O, Chai CS, Hao L, et al. Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells. Asian Pac J Cancer Prev 2013; 14: 5663-9.
45. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der Pluijm G. The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis. Clin Exp Metastasis 2011; 28: 615-25.
46. Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 2007; 6: 1403-12.
47. Kregel S, Kiriluk KJ, Rosen AM, et al. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One 2013; 8: 11.
48. Li X, Xu Y, Chen Y, et al. SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/beta-catenin signal network. Cancer Lett 2013; 336: 379-89.